Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
26 September, 2017 23:53 IST
Divis Lab receives import alert for Visakhapatnam facility
Source: IRIS | 21 Mar, 2017, 10.10AM
Comments  |  Post Comment

Divis Laboratories, a pharmaceutical ingredients and intermediates company, has received an Import Alert 66-40 from US Food and Drug Administration (USFDA) for its products manufactured at the company's Unit-II located at Visakhapatnam, Andhra Pradesh on March 20, 2017.

The agency has exempted the following products from the Import Alert-Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate, 2, 4-wing active ester.

The company along with third party consultants is currently working to address the concerns of the USFDA and is making all efforts to fully meet the compliance requirements. 

Shares of the company declined Rs 138.7, or 17.54%, to trade at Rs 652.00. The total volume of shares traded was 1,228,420 at the BSE (10.02 a.m., Tuesday).



Divis Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
GE Shipping takes delivery of secondhand medium gas carrier - 26-Sep-2017 11:37
Infosys accelerates private cloud adoption with OpenStack solution - 26-Sep-2017 10:09
SBI revises service charges on maintaining monthly average balance - 26-Sep-2017 10:04
Vivimed Labs inks pacts to facilitate investment of USD 42.5 mn - 26-Sep-2017 09:56
Gayatri Projects' JV bags order worth Rs 14.83 bn - 25-Sep-2017 15:15
Lupin receives USFDA approval for generic Clobex lotion - 25-Sep-2017 14:53
Suven Life Sciences secures product patents in India, Japan - 25-Sep-2017 12:10
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer